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Adipose tissue plays a central role in the pathogenesis of metabolic syndrome. Adiponectin (APN) is a bioactive adipocytokine
secreted from adipocytes. Low plasma APN levels (hypoadiponectinemia) are observed among obese individuals and in those
with related disorders such as diabetes, hypertension, and dyslipidemia. APN ameliorates such disorders. Hypoadiponectinemia
is also associated with major cardiovascular diseases including atherosclerosis and cardiac hypertrophy. Accumulating evidence
indicates that APN directly interacts with cardiovascular tissue and prevents cardiovascular pathology. Increasing plasma APN
or enhancing APN signal transduction may be an ideal strategy to prevent and treat the cardiovascular diseases associated with
metabolic syndrome. However, further studies are required to uncover the precise biological actions of APN.
1.Introduction
Obesity is one of the most common disorders in industrial-
ized countries and is fast becoming a worldwide health prob-
lem. Metabolicdisorders such as hypertension, dyslipidemia,
and glucose intolerance frequently, but not incidentally,
cluster in an individual with obesity, resulting in atheroscle-
roticcardiovascular diseases. This pathophysiology,based on
excess visceral fat accumulation, has been conceptualized as
“syndrome X,” “deadly quartet,” or “visceral fat syndrome,”
which are currently recognized as “metabolic syndrome [1].”
Adiposetissueplaysapivotalroleinmetabolicsyndrome.
Accumulating evidence indicates that adipose tissue secretes
a variety of bioactive adipocytokines such as tumor necrosis
factor (TNFα), plasminogen activator inhibitor type 1,
retinol binding protein-4, monocyte chemotactic protein-1,
and adiponectin (APN). Of these, APN has been cloned
and is the most abundant. In the past decade, a large
number of clinical and experimental studies have uncovered
a variety of biological functions for APN. This paper updates
the protective roles of APN in cardiovascular diseases and
discusses the association of APN with metabolic syndrome.
2.ClinicalFeaturesof LowPlasma APN
(Hypoadiponectinemia)
2.1. Obese Subjects and Patients with Coronary Risk Factors.
T h eﬁ r s tc l i n i c a ls t u d yo fA P Nw a sc o n d u c t e dt oo b s e r v e
plasma levels of APN among obese subjects. Although
plasma levels of most other adipocytokines are higher in
obese individuals, Arita et al. reported that plasma levels
of APN are lower in obese individuals and are negatively
correlated with body mass index (BMI) [2]. Subsequent
studies demonstrated that plasma APN is lower (hypoad-
iponectinemia) in patients with diabetes, hypertension, and
dyslipidemia than BMI-matched controls [3–5], indicating
that hypoadiponectinemia is associated with an increased
prevalence of coronary risk factors.
2.2. Coronary Artery Diseases. Subsequently, a series of
clinical studies reported an association between hypoad-
iponectinemia and coronary artery diseases (CAD). Plasma
APN is signiﬁcantly lower in patients with CAD than control
subjects, and male patients with hypoadiponectinemia have
a twofold increase in CAD prevalence, independent of well-2 Cardiology Research and Practice
knownrisk factors [6, 7].Another prospective study revealed
that high plasma APN concentrations are associated with
a lower risk for myocardial infarction in men, indepen-
dent of inﬂammation and glycemic status [8]. Moreover,
Otsuka et al. reported that patients with acute coronary
syndrome have lower APN levels than patients with stable
CAD and that plasma APN levels are signiﬁcantly associated
with coronary lesion complexity in men with CAD [9].
Several studies of patients undergoing percutaneous coro-
nary intervention (PCI) indicate that hypoadiponectinemia
is an independent predictor for in-stent restenosis [10,
11]. Recently, a multiple regression analysis revealed that
levels of high molecular weight (HMW) APN correlate
negatively with glycated hemoglobin in nondiabetic patients
but positively with high-density lipoprotein cholesterol in
diabetic patients with CAD [12]. These results indicate that
total or HMW hypoadiponectinemia is an independent risk
factor for CAD and that APN may directly protect against
abnormal vascular remodeling.
2.3. Cardiac Diseases. Obesity is strongly associated with
pathological cardiac remodeling, and several studies have
investigated the association between plasma APN levels and
cardiac diseases. Hypoadiponectinemia is associated with the
progression of left ventricular hypertrophy (LVH) with dias-
tolic dysfunction among patients with essential hypertension
[13]. Even among healthy subjects, APN concentration is
inversely and independently associated with LVH diagnosed
by electrocardiography in Japanese men [14]. Another study
using echocardiography revealed that circulating total APN
and HMW APN are related to left ventricular wall thickness
and diastolic function independent of age and metabolic
factors [15]. These data suggest that APN may regulate
hypertrophic progression of cardiomyocytes.
However, therole ofAPNin heart failure iscontroversial.
Several studies have shown that plasma APN levels are
high in patients with chronic heart failure (CHF) and are
associated with CHF severity or mortality despite the pro-
tective eﬀect of APN on CHF in mice [16–19]. β-blocker
therapy correlates with lower APN levels in patients with
CHF, especially in nonobese patients, suggesting that this
relationship should be considered when assessing plasma
APN among patients with CHF [20]. Further careful studies
may be required to clarify the relationship between APN and
heart failure.
2.4. Chronic Kidney Disease (CKD). Increased albuminuria
among patients with obesity and diabetes is a risk factor for
cardiovascular and renal disease, and patients with CKD are
at high risk for cardiovascular events. CKD patients show
higher plasma APN levels than healthy subjects due to the
low renal clearance rate of APN [21]. A prospective study
of patients with renal failure demonstrated that patients
who experience new cardiovascular events had lower plasma
APN levels than event-free patients [22]. Several other
studies have also indicated that increases in plasma APN
in patients with CKD decrease their risk for cardiovascular
disease and increase survival rate [23, 24]. In contrast, a
high APN level is associated with mortality, independent of
risk markers for CHF severity among patients with CKD
[16, 25]. Therefore, the cardioprotective role of APN in
CKD remains controversial. A recent report by Komura et al.
revealed that the loss of the vascular protective function of
APN in the presence of high cystatin C levelsin patients with
CKD indicates that cystatin C may mask the beneﬁcial eﬀect
of APNin patientswith CKDdespitehigh plasma APNlevels
[21].
3.Biological Featuresof APN
3.1. Atherosclerosis
3.1.1.In Vitro. Afterinitialclinicalﬁndings oftheassociation
between CAD and hypoadiponectinemia were reported,
several experimental studies have been conducted to elu-
cidate the biological eﬀect of APN in atherosclerosis. APN
has structural similarity with complimentary C1q or the
collagenfamilies [1].APNspeciﬁcally bindstocollagentypes
I, III, and V, which are present in vascular intima and
detected in the subendothelial space of rat balloon-injured
arteries, implying an interaction between APN and vascular
pathology [26].
When atherosclerosis commences, low-density lipopro-
tein (LDL) particles in the blood become oxidized (oxLDL)
and induce the expression of adhesion molecules such as
vascular cell adhesion molecule-1 (VCAM-1) and intercellu-
lar adhesion molecule-1, in endothelial cells (ECs). Leuko-
cytes in blood attach to the endothelial layer and induce
proinﬂammatory chemokines that attract leukocytes into
the subendothelial space [27]. APN inhibits the expression
of these adhesion molecules in TNFα-activated endothelial
cells by suppressing inﬂammatory transcriptional factors
and activating nuclear factor (NF)-κB[ 6, 28]. Additionally,
APN inhibits TNFα-inducible interleukin (IL)-8 synthesis
in ECs by inactivating NF-κB and activating Akt [29]. An
in vivo study in mice demonstrated that APN deﬁciency
increases leukocyte-endothelium interactions with impaired
endothelialnitric oxidesignaling (eNOS)via upregulation of
endothelial cell adhesion molecules [30].
The recruited inﬂammatory cells subsequently enhance
the oxidization of LDL and various inﬂammatory reactions.
Monocytes migrate to the subendothelial space in the
atherosclerotic lesion and become lipid-laden macrophages.
Monocytes change into macrophages in the subendothe-
lial space by taking up oxLDL via scavenger receptors
and form cells with accumulated cholesterol esters. APN
suppresses scavenger receptor type A (SR-A) in macro-
phages and the internal cholesterol ester content. However,
macrophages play an important role in reverse cholesterol
transport (RCT), a protective system against atherosclerosis.
APN increases apoA-I-mediated cholesterol eﬄux from
macrophages through an ATP-binding cassette transporter
A1-dependent pathway, indicating that APN may prevent
atherosclerosis by accelerating RCT [31]. Macrophages sus-
tain and amplify the inﬂammatory process by releasing
several growth factors, cytokines, and chemokines that
may further recruit immune cells, including monocyte/Cardiology Research and Practice 3
macrophages, T lymphocytes, or vascular smooth muscle
cells. Pretreatment with recombinant APN signiﬁcantly
suppresses the production of cytokines/chemokines, such
as TNFα, and CXCR3 ligand chemokines, such as IFN-
inducible protein of 10kDa (IP-10), monokine induced by
IFN-γ,and IFN-inducibleTcells, which is achemoattractant
in lipopolysaccharide-stimulated macrophages [32, 33]. The
inﬂammatory process includes enzymes that can destroy
the arterial extracellular matrix such as metalloproteinases
(MMPs). APN treatment also inducesanti-inﬂammatory IL-
10 and subsequent tissue inhibition of MMP-1 production,
suggesting that APN may stabilize atherosclerotic plaques
and prevent their rupture [34].
Aortic smooth muscle cells (AoSMCs) are another major
player in atherosclerosis, and their pathological migration
and proliferation in the intima relates to restenosis of coro-
nary arteries after PCI. APN suppresses growth factor-
stimulated AoSMCproliferation and migration by inhibiting
the ERK signal [35].
3.1.2. In Vivo. Several experimental studies have demon-
strated the eﬀect of APN on atherogenesis. The increment
of total APN or globular APN signiﬁcantly attenuates the
progression of atherosclerosis in apoE knockout mice [36,
37]. In atherosclerotic lesions, APN accumulates to form
cells in fatty streaks and inhibits the expression of VCAM-
1, SR-A, and TNFα [36]. In addition, APN/apoE double
knockout mice show advanced atherosclerotic lesions with
increased T-lymphocyte accumulation and higher plasma
IP-10 levels compared with apoE single knockout mice
(Figure 1)[ 33]. Moreover, APN deﬁciency worsens neointi-
mal formation after endothelial injury in mice, while APN
supplements reverse the abnormal vascular remodeling [38].
These data support the in vitro bioactivity of APN as an anti-
inﬂammatory adipocytokine in the atherosclerotic process.
3.2. Cardiac Diseases. Clinical studies have demonstrated
that APN is associated with myocardial pathophysiology.
APNdeﬁciencycausessevereconcentriccardiachypertrophy
in mice after pressure overload with increased extracellular
signal-regulated kinase, diminishes AMP-activated protein
kinase (AMPK) signaling in the myocardium, and increases
mortality [39]. Supplementing APN with an adenovirus
vector attenuates the pathological cardiac hypertrophy. In
an ischemia/reperfusion myocardium injury model, APN
knockout mice exhibit increases in myocardial infarct
size, apoptosis, and TNFα expression compared with con-
trols. In cultured cardiomyocytes, APN inhibits TNFα
production by inducing cyclooxygenase-2-dependent syn-
thesis of prostaglandin E 2 [40]. A similar experiment
showed that globular APN protects myocardium from
ischemia/reperfusion injurybyinhibitinginducibleNOSand
nicotinamide adenine dinucleotide phosphate oxidase pro-
tein expression and resultant oxidative/nitrate stress [41].
Two recent reports demonstrated that APN knockout mice
show enhanced cardiac ﬁbrosis following permanent ligation
of the left anterior descending artery or angiotensin II
infusion. APN accumulates in the injured cardiomyocytes
and protects it against ﬁbrosis by reducing apoptosis and
AMPK-dependent peroxisome proliferator-activated recep-
tor (PPARα)a c t i v a t i o n[ 19, 42]. Despite the potential
association between heart failure and high plasma APN
shown by several clinical studies, other experimental studies
have demonstrated a beneﬁcial, protective eﬀect of APN on
myocardium. Elevated plasma levels of APN among patients
with heart failure can be a reﬂection of accompanying renal
dysfunction or “APN resistance” including impaired APN
signal transduction in myocardium.
3.3. APN and Pulmonary Artery Remodeling. Pulmonary
arterial hypertension (PAH) is an idiopathic disease charac-
t e r i z e db ya ni n c r e a s ei nt h et h i c k n e s so fp u l m o n a r ya r t e r y
wall. APN suppresses platelet-derived growth factor BB-
mediated proliferation of pulmonary artery smooth muscle
cells harvested from mice [43], indicating that APN may
play a role in the prevention of PAH. In a mouse model
of chronic airway inﬂammation, APN deﬁciency causes
pathological pulmonary arterial wall thickness and elevates
right ventricular systolic pressure, indicating PAH [44].
APN knockout mice also show thickening of pulmonary
arterial wall under chronic hypoxic exposure, and APN
overexpression signiﬁcantly decreases the wall remodeling
and right ventricular hypertrophy [45].
3.4. APN and Endothelial Function, Angiogenesis, and Hyper-
tension. A P Ns e r v e sa sa na n g i o g e n i cf a c t o r .I nam o u s e
hindlimb ischemia model, APN deﬁciency impairs revascu-
larization, whereas adenovirus-mediated APN administra-
tion recovers angiogenesis [46]. APN stimulates blood vessel
growth in the in vivo mouse Matrigel plug implantation and
rabbit corneal models of angiogenesis by promoting cross-
talkbetweenAMP-activated proteinkinase andAktsignaling
within endothelial cells [47]. APN also dose dependently
suppresses endothelial cell apoptosis and proliferation,
migration, and premature diabetic senescence of endothelial
progenitor cells [48–50].
Hypoadiponectinemia is associated with impaired endo-
thelial dysfunction related to vasorelaxation. APN knockout
mice show a signiﬁcantly reduced endothelium-dependent
vasodilation in response to acetylcholine compared with
wild-type mice [51]. Another experiment demonstrated that
APN knockout mice develop hypertension when maintained
onahigh-salt diet(8%NaCl)withoutinsulin resistance [52].
Notably, all of these APNs protective eﬀects on endothelial
function are mediated through an increase in the production
of eNOS [51, 53–55].
3.5. APN Strategies for Cardiovascular Protection in Metabolic
Syndrome. Hypoadiponectinemia directly promotes the
pathological reactions in cardiovascular system (Figure 2).
Therefore, the increment of plasma APN is important to
maximize the beneﬁcial eﬀects of APN. A reduction in body
weight, especially visceral fat mass, with a combination of
diettherapyandexerciseisasafeandeﬀectivewaytoincrease
plasma APN levels.4 Cardiology Research and Practice
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Figure 1: APN deﬁciency in apoE knockout mice. Compared with apoE single knockout mice, APN/apoE double knockout mice showed
(a) higher plasma IP-10 levels, (b) advanced atherosclerosis, and (c) accelerated accumulation of T lymphocytes in atherosclerotic lesions
(Adapted from [33]).
Another strategy to prevent cardiovascular disease using
APN includes pharmacological changes in plasma APN
levels. PPARγ agonists signiﬁcantly increase plasma APN
concentrations in insulin-resistant humans without aﬀecting
their body weight and in a mouse model of oxygen-induced
retinopathy [56, 57]. Administering PPARα ligands and
angiotensin receptor blockers also increases plasma APN
levels [53, 58–60]. Furthermore, several statins are also
eﬀective for elevating plasma APN [61, 62]. Changes in
HMW APN as well as total APN may also be an ideal target.
The natriuretic peptides including atrial natriuretic peptide
(ANP) and brain natriuretic peptide (BNP) also increased
the production of APN in adipocytes and plasma APN levels
amongpatientswithcongestiveheart failure[63].Exogenous
administration of adiponectin may be a therapeutic strategy
as well. In a pig model, a single intracoronary adminis-
tration of recombinant adiponectin protected myocardial
ischemia/reperfusion injury by suppressing inﬂammation,
apoptosis and oxidative stress [64].
APN receptors or candidate APN-receptor-binding pro-
teins have been reported such as AdipoR1-R2, T-cadherin,
and calreticulin [65–67] .V e ryr e c e n t l y ,De n z e le ta l .r e p o rt e d
that T-cadherin (glycosyl phosphatidylinositol-anchored cell
surface glycoprotein) is critical for adiponectin-mediated
cardioprotection by showing no eﬀect of adenovirus-
mediated adiponectin supplement in T-cadherin knockoutCardiology Research and Practice 5
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Figure 2: Hypoadiponectinemia directly promotes the pathological reactions in cardiovascular system.
mice [68]. Pharmacologically enhancing the expression of
or activating APN receptors may be a good strategy for
cardiovascular protection.
4.Conclusion
Adipose tissue stores not only excess body energy but also
a variety of adipocytokines that regulate cardiovascular
homeostasis directly and indirectly. Accumulating evidence
has demonstrated that APN prevents diabetes, dyslipidemia,
and hypertension, which are well-known risk factors for
cardiovascular disease. Notably, APN directly interacts with
cardiac and vascular tissues and mitigates pathological
reactions. Generally, anti-inﬂammation is a key biological
action of APN for cardiovascular protection. Further clinical
and experimental studies will clarify the precise eﬀects and
mechanisms of APN action for future clinical use.
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